Abstract
N ewcastle Disease (ND) is both respiratory and digestive disease s in poultry caused by avian paramyxovirus type 1 (APMV-1). Field data show ed that there wer e still many cases of Newcastle Disease faced by farmers despite of vaccination programs had been done routinely. The aim of this research is to find out the effectiv eness of some routine ND vaccination program in broiler chiken challenge d either with viscerotropic velogenic Newcastle Disease (VVND) virus or virulent ND virus from field isolate s . One hundred b roiler chickens were divided into 4 groups of 25 each . In the G roup I , vaccination was carried out at day 1 with combination of ND-IB live vaccine and ND killed vaccine, and booster at day 18 with live ND vaccine , i n the G roup II , chickens were vaccinated with live ND-IB vaccine at day 1 and day 18 and in the G roup III , chickens were vaccinated with live ND-IB vaccine at day 1 and vaccinated with ND live vaccine at day 18. Challenge test performed in twenty broiler chickens of each group with virulent ND that has chicken lethal dose fifty (CLD 50 ) 4,8. Virus preparation 2 6 and then diluted to 10 -4 , to obtain dilution 10000. Twenty chicken from each group w ere then given 0.5 cc dilution of 6 HA virulent virus at 28 days of old . Six challenged chicken from group I showed ND clinical symptom and were even tually death . T his mean that the vaccine program provide d 70% protection. Whereas all challenged chicken from the G roup s II and III were sick , then died mean ing that these vaccination program s did not give any protection at all. Bsed on the present study, it is concluded that the administration of ND live vaccine priming along with ND killed vaccine is needed to improve the protection against velogenic NDV. Normal 0 false false false EN-US X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:Table Normal; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:8.0pt; mso-para-margin-left:0in; line-height:107%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:Calibri,sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Times New Roman; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin;}
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.